FEBRUARY 9, 2021 • 12:00 PM – 3:00 PM ET

With a new Administration in place, many are eager to see what changes are potentially in store for the 340B Drug Pricing Program and other health care initiatives that directly and indirectly affect it and its key stakeholders. While still in the midst of pandemic response efforts and taking into consideration any other legislative, regulatory, and judicial actions expected in 2021, we’ll examine the most pressing issues impacting those directly involved with 340B efforts at their organization. In this third iteration, the day-long webinar series continues the conversation for and between covered entities and manufacturers with a reflection on potential policies and developments as a result of the new Administration, the continuing dispute between providers and manufacturers around contract pharmacy arrangements, and insight on business practices that will help your organization with its 340B efforts. Participate in one or all of the sessions of the day to gain insight into the current climate and strategies to improve your operations, such as addressing duplicate discounts, getting the most out of your data, and ensuring program integrity and compliance.

Webinar Agenda:

12:00 – 1:00 pm Threats and Opportunities in the 340B Program – An Update on Recent Business, Legislative, and Policy Developments
This opening session looks at the most recent developments impacting the 340B Drug Pricing Program and its key stakeholders. Our panel evaluates the current climate in relation to the political, legislative, judicial, and business activity occurring and gives insight into what covered entities, HRSA grantees, pharmacies, distributors, and manufacturers should watch.

• Gain insight into what Democratic control of the three branches of government may mean for the program
• Hear thoughts surrounding the direction of HHS, under Secretary nominee Xavier Becerra, in relation to various policies and reforms that would directly or indirectly impact the program
• Explore any potential state legislation in 2021 that may be brought to the table to impact or improve the program
• Discuss the HRSA Final Rule to establish an ADR (administrative dispute resolution) process and panels to resolve certain disputes between CEs and manufacturers
• Examine reaction to the HHS General Counsel’s Dec. 30 advisory opinion on 340B contract pharmacy and updates surrounding the lawsuits, rulings, and implications related to the continuing contract pharmacy dispute between providers and some manufacturers

---

1:00 – 2:00 pm Don’t Get WAC’d – Minimizing WAC Exposure for DSH and PED Hospitals
This session reviews the definition and reason for the WAC account and how to recognize good WAC spend vs. unnecessary WAC spend. Also hear ways to identify unnecessary WAC purchases prior, during and post order, as well as troubleshoot root causes. Lastly, discuss the impact of WAC spend with the new 340B Kalderos Rebate Model and learn about a plan of action to prevent future unnecessary WAC spend. 

• Review WAC accounts
• Share best practices for minimizing WAC exposure
• Examine the impact of the 340B Kalderos Rebate Model

---

2:00 – 3:00 pm Session TBA

Speaking and sponsorship opportunities still available. Please contact Gina.Glendening@worldcongress.com for details.

---